A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Hoyle, Margaret [1 ]
Paccagnella, Luisa [2 ]
机构：
[1] Pfizer, Milan, Italy
[2] Pfizer Inc, Groton, CT 06340 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181202
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [11] A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Czuczman, Myron S.
    Trneny, Marek
    Davies, Andrew
    Rule, Simon
    Linton, Kim M.
    Wagner-Johnston, Nina
    Gascoyne, Randy D.
    Slack, Graham W.
    Brousset, Pierre
    Eberhard, David A.
    Hernandez-Ilizaliturri, Francisco J.
    Salles, Gilles
    Witzig, Thomas E.
    Zinzani, Pier Luigi
    Wright, George W.
    Staudt, Louis M.
    Yang, Yandan
    Williams, P. Mickey
    Lih, Chih-Jian
    Russo, Jacqueline
    Thakurta, Anjan
    Hagner, Patrick
    Fustier, Pierre
    Song, Dale
    Lewis, Ian D.
    CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4127 - 4137
  • [12] Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
    Zinzani, Pier Luigi
    Pellegrini, Cinzia
    Gandolfi, Letizia
    Stefoni, Vittorio
    Quirini, Federica
    Derenzini, Enrico
    Broccoli, Alessandro
    Argnani, Lisa
    Pileri, Stefano
    Baccarani, Michele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06): : 462 - 466
  • [13] The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Delgado, Julio
    Papadouli, Irene
    Sarac, Sinan B.
    Moreau, Alexandre
    Hovgaard, Doris
    Gisselbrecht, Christian
    Enzmann, Harald
    Pignatti, Francesco
    HEMASPHERE, 2021, 5 (12): : E666
  • [14] A Phase 1/1b Open-Label, Multicenter, Two- Part Study of SETD2 Inhibitor EZM0414 in Patients with Relapsed/Refractory Multiple Myeloma or Diffuse Large B-Cell Lymphoma
    Richardson, Paul G.
    Niesvizky, Ruben
    Yang, Jay
    Yadav, Neelu
    Hsu, Helen
    Flowers, Christopher R.
    BLOOD, 2021, 138
  • [15] Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
    Cheah, Chan Yoon
    Belada, David
    Fanale, Michelle A.
    Janikova, Andrea
    Czucman, Myron S.
    Flinn, Ian W.
    Kapp, Amy V.
    Ashkenazi, Avi
    Kelley, Sean
    Bray, Gordon L.
    Holden, Scott
    Seymour, John F.
    LANCET HAEMATOLOGY, 2015, 2 (04): : E166 - E174
  • [16] A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ward, Jeffrey P.
    Thein, Jessica
    Luo, Jingqin
    Wagner-Johnston, Nina D.
    Cashen, Amanda F.
    Fehniger, Todd A.
    Bartlett, Nancy L.
    BLOOD, 2015, 126 (23)
  • [17] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
    Palomba, M. Lia
    Till, Brian G.
    Park, Steven I.
    Morschhauser, Franck
    Cartron, Guillaume
    Marks, Reinhard
    Shivhare, Mahesh
    Hong, Wan-Jen
    Raval, Aparna
    Chang, Alice C.
    Penuel, Elicia
    Popplewell, Leslie L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E443 - E451
  • [18] Estimation of Long-Term Survival with Tafasitamab plus Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Salles, Gilles
    Goswami, Budhaditya
    Bagnardi, Vincenzo
    Dey, Debarshi
    Winderlich, Mark
    Ambarkhane, Sumeet
    Huang, Dan
    Nowakowski, Grzegorz S.
    BLOOD, 2020, 136
  • [19] COST-EFFECTIVENESS ANALYSIS OF TAFASITAMAB IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN GREECE
    Karaiskou, M.
    Avgitidou, A.
    Vostitsanou, Z.
    Batsi, M.
    Bungey, G.
    Prawitz, T.
    Peter, B.
    Stafylas, P.
    VALUE IN HEALTH, 2023, 26 (12) : S151 - S151
  • [20] Efficacy and safety of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
    Habermann, T.
    Lossos, I.
    Justice, G.
    Tuscano, J.
    Cole, C.
    Vose, J.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Wiernik, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 150 - 150
12345